ArticleCancer medicine2018
Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma.
Jimin Dai et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this papercites it